• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Pipeline

Pipeline

July 26, 2021
Company Drug/Device Medical Condition Status
Organicell Regenerative Medicine Zofin COVID-19 long-haulers IND approved by the FDA for phase 1/2 trial
Viracta Therapeutics nanatinostat and valganciclovir EBV+ recurrent or metastatic nasopharyngeal carcinoma (RM-NPC) and other EBV+ solid tumors. IND approved by the FDA for a phase 1b/2 trial
YishengBio PIKA recombinant COVID-19 vaccine COVID-19 prevention IND approved by the United Arab Emirates Ministry of Health & Prevention
KeifeRx Nilotinib BE dementia due to Alzheimer's disease IND approved by the FDA for phase 3 trial
Antengene ATG-101 metastatic/advanced solid tumors and B-cell nonHodgkin's lymphoma phase 1 trial authorized by the Bellberry Human Research Ethics Committee in Australia
Ascletis Pharma ASC40 combined with bevacizumab recurrent glioblastoma phase 3 trial authorized by China’s National Medical Products Administration
InDex Pharmaceuticals cobitolimod moderate-to-severe left-sided ulcerative colitis phase 3 trial authorized by the Swedish Medical Products Agency
Advaxis ADXS-504 patients with biochemically recurrent prostate cancer initiation of phase 1 trial
Synlogic SYNB1934 phenylketonuria initiation of phase 1 trial
Eureka Therapeutics ECT204 hepatocellular carcinoma initiation of phase 1/2 trial
Prometheus Biosciences PRA023 moderate-to-severe ulcerative colitis initiation of phase 2 trial
Vertex Pharmaceuticals VX-548 acute pain following abdominoplasty surgery initiation of phase 2 trial
Vir Biotechnology VIR-2218 and VIR-3434 chronic hepatitis B virus initiation of phase 2 trial
Rain Therapeutics milademetan (RAIN-32) de-differentiated liposarcoma initiation of phase 3 trial
Albireo Pharma Bylvay (odevixibat) progressive familial intrahepatic cholestasis approved by the FDA
Astellas Prograf (tacrolimus) prevention of organ rejection in adult and pediatric lung transplant recipients approved by the FDA for expanded indication
Kadmon Holdings Rezurock (belumosudil) patients 12 years and older with chronic graft-vs.-host disease approved by the FDA
Merck Vaxneuvance (pneumococcal 15-valent conjugate vaccine) active immunization against invasive pneumococcal disease in adults caused by 15 serotypes approved by the FDA
Merck

Eisal
Keytruda (pembrolizumab) plus Lenvima (lenvatinib) advanced endometrial carcinoma approved by the FDA
Octapharma USA Octagam 10 percent intravenous immunoglobulin adult dermatomyositis approved by the FDA
Nevro Senza system chronic pain associated with painful diabetic neuropathy approved by the FDA
bluebird bio Skysona (elivaldogene autotemcel, Lenti-D gene therapy) treatment of patients under age 18 who have early cerebral adrenoleukodystrophy without matched sibling donor approved by the European Commission
Astra Zeneca

Merck
Koselugo (selumetinib) symptomatic, inoperable plexiform neurofibromas in children under age three with neurofibromatosis type 1 approved by the European Commission
Myovant Sciences Ryeqo (relugolix 40 mg, estradiol 1.0 mg and norethindrone acetate 0.5 mg) uterine fibroids approved by the European Commission
Regeneron Pharmaceuticals Ronapreve (casirivimab and imdevimab) mild-to-moderate COVID-19 approved in Japan

 

Upcoming Events

  • 16Feb

    Fundamentals of FDA Inspection Management: Reduce Anxiety, Increase Inspection Success

  • 21May

    WCG MAGI Clinical Research Conference – 2023 East

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • Revamp-360x240.png

    Califf Calls for Major Evidence Generation Revamp, Experts’ Opinions Differ

  • AskTheExpertsGreen-360x240.png

    Ask the Experts: Managing Investigational Products

  • SurveywBlueBackground-360x240.png

    Survey Outlines Site Challenges, Successes on Diversity

  • PatientCentricity-360x240.png

    Site Spotlight: DM Clinical Shows Patient Centricity Doesn’t Have to Break the Bank

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell or Share My Data

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing